China Biologic Products Holdings Inc (CBPO) |
|
|
|
China Biologic Products Holdings Inc Growth Comparisons
Select each growth Category to receive further Information
Select the Comparisons :
|
|
Select the Ratio:
|
|
CBPO's Growth Comparisons in IV. Quarter 2019
China Biologic Products Holdings Inc 's Revenue slowed to the 7.9% year on year, improvement in the forth quarter 2019 to 504 millions, underperforming the 8.35% growth in the Biotechnology & Pharmaceuticals industry, but beating the 3.53% growth in the Healthcare sector. Above the average sales gains in the Healthcare and in the Biotechnology & Pharmaceuticals industry as well, helped to elevate overall market growth to 1.72%. Sequentially company's Revenue were unchanged from the third quarter results. . Looking into annual growth, sales grew by 15.67% on average in last five years, while S & P 500's including only Businesses with the forth quarter 2019 earnings reports, average yearly sales growth is 10.53%.
Growth Rates of CBPO's Income in the forth quarter 2019
CBPO's EPS Growth Rates
China Biologic Products Holdings Inc reported bottom-line of $ 0.00 in the forth quarter, compare to $ 3.53 in the same quarter a year ago. Biotechnology & Pharmaceuticals industry grew by 8.35%, while Healthcare sector increased by 3588.76%, and overall market declined by -5.61%. Sequentially company's EPS were unchanged from the third quarter results. . Looking into annual growth, income per share grew by 15.67% on average in the last five years, while the S & P 500's including only the businesses with the forth quarter 2019 financial results, average yearly income per share growth is 11.58%.
CBPO Cash Flow Growth Rates
|